TransCode Therapeutics Reports Positive Phase 1a Data for TTX-MC138

The clinical data, current as of September 1, 2026, highlights the durability of the treatment in a heavily pretreated population. Beyond the initial stable disease response, 57.1% of patients maintained disease control through three months, while three individuals remained progression-free at the one-year mark. Researchers utilized the Growth Modulation Index to assess efficacy, finding that 40% of evaluable patients experienced at least a 30% longer progression-free interval compared to their previous systemic therapies.

Exploratory blood RNA-sequencing provided biological context for these clinical observations, revealing treatment-associated immune activation. Patients who achieved stable disease displayed increased cytotoxic activity and higher levels of M1-associated inflammatory markers. Medical consultant Daniel Vlock noted that the alignment between clinical outcomes and transcriptomic evidence supports the ongoing development of the drug. TransCode Therapeutics plans to integrate these findings into a formal study report as it prepares for further dose-expansion strategies and continued clinical evaluation.